Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRP9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $56,605
Award facts
- Contract value 100% obligated
- $56,604.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $56,604.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The delivery order, issued on December 12, 2025, with an ultimate completion date of December 15, 2025, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award represents one of numerous delivery orders DMS Pharmaceutical Group has received under its broader Indefinite Delivery Contract with the DLA.
This delivery order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.9 billion ceiling value and extends through December 31, 2036. The PPV-G GEN V program is a $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply chains across Department of Defense healthcare facilities worldwide. Under this contract vehicle, the DLA issues firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables. Trikafta, a cystic fibrosis treatment, represents the specialized pharmaceutical products within DMS Pharmaceutical Group's extensive portfolio supporting military medical operations.
Quick answers
Who was awarded contract SPE2DR26FCRP9?
SPE2DR26FCRP9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FCRP9 worth?
The government has obligated $56,605 on SPE2DR26FCRP9.
Is contract SPE2DR26FCRP9 an order under another contract?
Yes. SPE2DR26FCRP9 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRP9 competed?
The extent of competition for SPE2DR26FCRP9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award